This study is in progress, not accepting new patients
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Mirati Therapeutics Inc.
- Links
- BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting
- ID
- NCT03906071
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 577 people participating
- Last Updated